新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
Abstract
Provided herein are novel indazole compounds as PKMYT1 kinase inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
摘要
本文提供了作为PKMYT1激酶抑制剂的新型吲唑化合物、药物组合物、此类化合物在治疗癌症中的用途以及制备此类化合物的方法。
相似文献
1
Novel Indazole Compounds as PKMYT1 Kinase Inhibitors for Treating Cancer.新型吲唑化合物作为治疗癌症的PKMYT1激酶抑制剂
ACS Med Chem Lett. 2024 Oct 12;15(11):1810-1811. doi: 10.1021/acsmedchemlett.4c00486. eCollection 2024 Nov 14.
2
Novel Compounds as CDK2 Inhibitors for Treating Cancer.新型化合物作为治疗癌症的CDK2抑制剂
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
3
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.作为用于治疗癌症的细胞外信号调节激酶5（ERK5）抑制剂的吡咯并吡嗪化合物
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
4
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.作为用于治疗癌症的CD73抑制剂的新型双环杂环化合物。
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
5
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
6
Novel Phenylpiperidine Derivatives as QPCT and QPCTL Inhibitors for Treating Cancer or Fibrotic Diseases.新型苯基哌啶衍生物作为QPCT和QPCTL抑制剂用于治疗癌症或纤维化疾病。
ACS Med Chem Lett. 2024 Oct 30;15(11):1826-1827. doi: 10.1021/acsmedchemlett.4c00495. eCollection 2024 Nov 14.
7
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.作为用于治疗阿尔茨海默病和帕金森病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
8
Novel Cyanopyridine Compounds as KHK Inhibitors for Treating NAFLD, NASH, and Type II Diabetes.新型氰基吡啶化合物作为治疗非酒精性脂肪性肝病、非酒精性脂肪性肝炎和II型糖尿病的KHK抑制剂
ACS Med Chem Lett. 2024 Jul 23;15(8):1191-1192. doi: 10.1021/acsmedchemlett.4c00332. eCollection 2024 Aug 8.
9
Bicyclic Ureas as JAK2 Inhibitors for Treating Hematological Cancer.双环脲类化合物作为治疗血液系统癌症的JAK2抑制剂
ACS Med Chem Lett. 2024 Oct 29;15(11):1824-1825. doi: 10.1021/acsmedchemlett.4c00496. eCollection 2024 Nov 14.
10
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
本文引用的文献
1
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.癌症合成致死性的新视野：当前的发展和未来的展望。
J Med Chem. 2024 Jul 25;67(14):11488-11521. doi: 10.1021/acs.jmedchem.4c00113. Epub 2024 Jul 2.
2
Mechanisms and clinical landscape of N6-methyladenosine (m6A) RNA modification in gastrointestinal tract cancers.胃肠道癌症中N6-甲基腺苷（m6A）RNA修饰的机制与临床概况
Mol Cell Biochem. 2024 Jul;479(7):1553-1570. doi: 10.1007/s11010-024-05040-x. Epub 2024 Jun 10.
3
Crosstalk between lncRNAs and Wnt/β-catenin signaling pathways in lung cancers: From cancer progression to therapeutic response.肺癌中长链非编码RNA与Wnt/β-连环蛋白信号通路之间的串扰：从癌症进展到治疗反应
Noncoding RNA Res. 2024 Mar 14;9(3):667-677. doi: 10.1016/j.ncrna.2024.02.013. eCollection 2024 Sep.
4
Adavosertib and beyond: Biomarkers, drug combination and toxicity of WEE1 inhibitors.阿伐司他昔及其他：WEE1抑制剂的生物标志物、药物联合应用及毒性
Crit Rev Oncol Hematol. 2024 Jan;193:104233. doi: 10.1016/j.critrevonc.2023.104233. Epub 2023 Dec 14.
Zotero 插件